Archive

Neovasc’s Tiara and Reducer to be Featured at TCT 2018 Conference

NASDAQ, TSX: NVCN VANCOUVER, Sept. 20, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More

Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany

NASDAQ, TSX: NVCN VANCOUVER, Sept. 19, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...

Read More

Neovasc Announces Effective Date of Share Consolidation

NASDAQ, TSX: NVCN VANCOUVER, Sept. 18, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...

Read More

Neovasc Provides Initial Comments on Lawsuit

NASDAQ, TSX: NVCN VANCOUVER, Sept. 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More

Neovasc Announces Second Quarter 2018 Financial Results

NASDAQ, TSX: NVCN First implant of a Neovasc Reducer™ in a U.S. patient Reducer Q2, 2018 revenue up 64% over Q2, 2017 and at 108% of Q2, 2018 plan Tiara™ featured in live case at 11th Annual TVT conference Receipt of proceeds of US$13.1 million from exercise of Series...

Read More